This summer, the NCL urged the FDA to preserve access to safe fluoride options for families in communities without fluoridated water, emphasizing the importance of preventive oral health.

In November, NCL submitted detailed comments on the acetaminophen policy, countering misleading proposals regarding Tylenol labeling and reinforcing the need for clear, evidence-based consumer guidance. Additionally, NCL played a key role in advocating for the removal of the outdated boxed warning on local estrogen, an essential therapy for menopause-related symptoms, a change the FDA ultimately implemented. Collectively, these efforts highlight NCL’s ongoing commitment to advancing sound public health policy and strengthening consumer protections.